Dabrafenib-trametinib in BRAF V600-mutated non-small-cell lung cancer: a single center real world experience

Future Oncol. 2024;20(24):1745-1751. doi: 10.1080/14796694.2024.2340898. Epub 2024 May 6.

Abstract

Aim: We retrospectively evaluated the effect of dabrafenib/trametinib combination in patients with BRAF-mutated non-small-cell lung cancer (NSCLC) treated in a single center from 2017 to 2022.Patients: The response and safety data of 42 patients (27 treated in first-line and 15 as second/subsequent lines) were analyzed.Results: The objective response was 73.8%, with no differences between patients undergoing first- or second-line. A longer, statistically significant median progression-free survival (PFS) was observed in patients receiving the combination in first-line vs those in the second/subsequent lines (19.9 months [95% CI: 19.7-20] vs 13.1 months [95% CI: 8.6-17.6], respectively; p = 0.012). The median overall survival (OS) was 29.9 months (95% CI: 14.1-45.7) for patients treated with the combination in first-line and 22.4 months (95% CI: 14.6-30.2) for those treated in subsequent lines. The combination was well toleratedConclusion: We confirm the efficacy of dabrafenib/trametinib in BRAF-V600-mutated NSCLC.

Keywords: BRAF mutation; NSCLC; drug combination; efficacy; real life.

Plain language summary

[Box: see text].

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols* / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols* / therapeutic use
  • Carcinoma, Non-Small-Cell Lung* / drug therapy
  • Carcinoma, Non-Small-Cell Lung* / genetics
  • Carcinoma, Non-Small-Cell Lung* / mortality
  • Carcinoma, Non-Small-Cell Lung* / pathology
  • Female
  • Humans
  • Imidazoles* / administration & dosage
  • Imidazoles* / adverse effects
  • Imidazoles* / therapeutic use
  • Lung Neoplasms* / drug therapy
  • Lung Neoplasms* / genetics
  • Lung Neoplasms* / mortality
  • Lung Neoplasms* / pathology
  • Male
  • Middle Aged
  • Mutation*
  • Oximes* / administration & dosage
  • Oximes* / adverse effects
  • Oximes* / therapeutic use
  • Progression-Free Survival
  • Proto-Oncogene Proteins B-raf* / genetics
  • Pyridones* / administration & dosage
  • Pyridones* / adverse effects
  • Pyridones* / therapeutic use
  • Pyrimidinones* / administration & dosage
  • Pyrimidinones* / adverse effects
  • Pyrimidinones* / therapeutic use
  • Retrospective Studies

Substances

  • Proto-Oncogene Proteins B-raf
  • dabrafenib
  • Imidazoles
  • Oximes
  • trametinib
  • BRAF protein, human
  • Pyridones
  • Pyrimidinones